NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies

CLEVLAND, OH / ACCESSWIRE / June 1, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the formation of its Precision Medicine Division to enable more enhanced and accelerated personalized therapeutics and treatment protocols. Using AI, Big Data and Predictive technologies to power its new Precision Medicine Division, NovAccess Global will search through licensed databases to identify patient data (phenotypic, clinical and genomic) for analysis as part of its own and its clients therapeutic drug development and its clients' therapeutic treatment purposes. This service platform also will be marketed to external pharmaceutical and biotechnology companies, private payers, federal and national/international health agencies and healthcare providers.

According to Market.us, the global precision medicine market size was $83.4 billion in 2022 and is projected to reach $254 billion by 2032, exhibiting a compounded annual growth rate of 12.1% in the forecast period (2023-2032).

"At a time when AI is making headlines globally, we are taking a tremendous step forward as an early adopter in harnessing this technology's potential for healthcare and humanitarian purposes," said NovAccess Global's Chief Executive Officer Dr. Dwain K. Irvin. "The Company's strategic development plan has at its core a platform for targeted and personalized immunotherapies which leverages patient data to determine the appropriate course of treatment. Our executive team has spent considerable time formulating a natural extension of these activities. Our new Precision Medicine Division uses AI, Big Data and Predictive Technology to provide an important expansion to our core immunotherapy business which targets glioblastoma/brain tumors as an initial indication for targeted therapeutics. Today, we are very excited to publicly announce our formal launch of the service that utilizes the same approach for collecting and analyzing data for all forms of healthcare therapies."

Beyond the glioblastoma/brain tumor segment, NovAccess Global will target cardiology and oncology patient data, with an emphasis on obtaining oncology and cardiology patient data sets from different countries around the world that will include underrepresented patient populations. The Precision Medicine Division has begun developing a platform to allow the analysis of patient data in a manner that will meet the most stringent data privacy requirements. Overall, NovAccess Global expects to have its patient data platform available for commercial use by the end of the first quarter of 2024.